Abcam, ab247894, Anti-Proteasome 20S C2/HC2 antibody [EPR5452] - BSA and Azide free

Size: 100µg / 1mg
Rabbit Recombinant Monoclonal PSA1 antibody. Carrier free. Suitable for IHC-P, WB and reacts with Human samples.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EPR5452,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WB, IHC-PSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
ab247894 is the carrier-free version of
ab109530
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies
Conjugation ready
Our carrier-free antibodies are typically supplied in a PBS-only formulation, purified and free of BSA, sodium azide and glycerol. This conjugation-ready format is designed for use with fluorochromes, metal isotopes, oligonucleotides, and enzymes, which makes them ideal for antibody labelling, functional and cell-based assays, flow-based assays (e.g. mass cytometry) and Multiplex Imaging applications.
Use our
conjugation kits
for antibody conjugates that are ready-to-use in as little as 20 minutes with 1 minute hands-on-time and 100% antibody recovery: available for fluorescent dyes, HRP, biotin and gold.
Compatibility
This product is compatible with the Maxpar
Antibody Labeling Kit from Fluidigm, without the need for antibody preparation. Maxpar
is a trademark of Fluidigm Canada Inc.

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions-+4°C, Storage information-Do Not Freeze

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The Proteasome 20S C2/HC2 also known as the proteasome subunit beta type-1 represents an important component of the proteasome complex. This protein performs proteolytic functions degrading ubiquitinated proteins into peptides. The proteasome 20S C2/HC2 has a molecular mass of approximately 23 kDa and is expressed in various tissues throughout the body including muscle and nerve tissues. It forms part of the 20S core particle of the proteasome complex and contributes to protein homeostasis.
Biological function summary
Proteasome 20S C2/HC2 plays a significant role in maintaining protein quality by participating in proteolytic degradation. It forms part of the larger 26S proteasome complex which assembles with regulatory particles for substrate recognition. This protein is essential for the breakdown and removal of oxidized or misfolded proteins thereby preventing the accumulation of potentially toxic aggregates within the cell. It ensures cellular regulation by processing proteins that control various aspects of cell cycle signaling and differentiation.
Pathways
The activity of the Proteasome 20S C2/HC2 integrates directly into the ubiquitin-proteasome pathway. This pathway regulates protein turnover and plays a vital role in cellular processes such as the cell cycle and apoptosis. The association with proteins such as ubiquitin and E3 ligases is critical for the marking of substrate proteins for degradation. This protein is also linked to the NF-kB signaling pathway interacting with proteins that modulate immune and inflammatory responses demonstrating its influence on broader regulatory networks.
Proteasome 20S C2/HC2 disruption has been identified in various pathological conditions. Abnormal function or expression levels relate to neurodegenerative disorders like Parkinson’s disease where inefficient protein degradation leads to protein aggregation. This protein also connects to tumor progression in cancers where alterations in the ubiquitin-proteasome system affect cell cycle regulation and apoptosis. The protein's interaction with tumor suppressors and oncogenes highlights its significance in cellular growth abnormalities.